The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Lessons from the US: NCCN guidelines enable early access to novel MCL treatments
Yucai Wang, MD, PhD, Mayo Clinic, Rochester, MN, discusses global management of mantle cell lymphoma (MCL), highlighting the lack of a uniform standard of care in both the frontline and relapsed settings. Dr Wang explains how NCCN guidelines in the US can enable earlier access to emerging therapies before formal labeling for patients in need. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, I think just like other regions of the world, probably there’s no standard care for frontline, even for relapsed mantle cell lymphoma. But in the United States, I think one thing we are fortunate to have is the NCCN guideline, or similar other guidelines, allowing us to use some of the drugs early. And for example, the bispecific antibody, although not having an official label yet, by being on the existing guideline, we are able to access those drugs for patients who are in need...
Yeah, I think just like other regions of the world, probably there’s no standard care for frontline, even for relapsed mantle cell lymphoma. But in the United States, I think one thing we are fortunate to have is the NCCN guideline, or similar other guidelines, allowing us to use some of the drugs early. And for example, the bispecific antibody, although not having an official label yet, by being on the existing guideline, we are able to access those drugs for patients who are in need. So I understand that’s not the case everywhere in the world. So we’re interpreting some of the sort of retrospective data, especially survival outcome data coming out of the United States. Just know that we sometimes may have access to the efficacious agents earlier than other parts of the world. So just the interpretation of the data may be a little cautious there.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
